SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

                                 SCHEDULE 13G
                                (Rule 13d-102)


             INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
           TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
                           PURSUANT TO RULE 13d-2(b)

                                (Amendment No.5)


                         Bentley Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
                                (Name of Issuer)


                                  Common Stock
--------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                   082657107
--------------------------------------------------------------------------------
                                 (CUSIP Number)












                                 (Page 1 of 5)


CUSIP No. 082657107                  13G                       Page 2 of 5 Pages


________________________________________________________________________________
1.   NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     Renaissance US Growth and Income Trust PLC                             None
________________________________________________________________________________
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                 (a)  [_]
                                                                 (b)  [_]
________________________________________________________________________________
3.   SEC USE ONLY


________________________________________________________________________________
4.   CITIZENSHIP OR PLACE OF ORGANIZATION

     United Kingdom
________________________________________________________________________________
  NUMBER OF    5.   SOLE VOTING POWER

   SHARES           904,400
               _________________________________________________________________
BENEFICIALLY   6.   SHARED VOTING POWER

  OWNED BY          None
               ________________________________________________________________
    EACH       7.   SOLE DISPOSITIVE POWER

  REPORTING         904,400
               _________________________________________________________________
   PERSON      8.   SHARED DISPOSITIVE POWER

    WITH            None
________________________________________________________________________________
9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


     904,400
________________________________________________________________________________
10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

                                                                          [_]

________________________________________________________________________________
11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9


     6.15%
________________________________________________________________________________
12.  TYPE OF REPORTING PERSON*


     IV
________________________________________________________________________________
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!




CUSIP No. 082657107                   13G                      Page 3 of 5 Pages



Item 1(a).  Name of Issuer:

            Bentley Pharmaceuticals, Inc.                            ("Company")
            ____________________________________________________________________

Item 1(b).  Address of Issuer's Principal Executive Offices:

            4890 West Kennedy Blvd., #400
            Tampa, FL  33609
            ____________________________________________________________________

Item 2(a).  Name of Person Filing:

            Renaissance US Growth and Income Trust PCL                 ("Filer")
            ____________________________________________________________________

Item 2(b).  Address of Principal Business Office, or if None, Residence:
            8080 North Centray Expressway
            Suite 210, LB-59
            Dallas, TX  75206-1857
            ____________________________________________________________________

Item 2(c).  Citizenship:

            United Kingdom
            ____________________________________________________________________

Item 2(d).  Title of Class of Securities:

            Common Stock
            ____________________________________________________________________

Item 2(e).  CUSIP Number:

            75966V105
            ___________________________________________________________________

Item 3.     If This Statement  is Filed  Pursuant to  Rule 13d-1(b), or 13d-2(b)
            or (c), Check Whether the Person Filing is a:

     (a)  [_]  Broker or dealer registered under Section 15 of the Exchange Act.

     (b)  [_]  Bank as defined in Section 3(a)(6) of the Exchange Act.

     (c)  [_]  Insurance  company as defined in Section 3(a)(19) of the Exchange
               Act.

     (d)  [_]  Investment  company  registered under Section 8 of the Investment
               Company Act.

     (e)  [_]  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     (f)  [_]  An employee  benefit plan or endowment  fund in  accordance  with
               Rule 13d-1(b)(1)(ii)(F);

     (g)  [_]  A parent  holding  company or control  person in accordance  with
               Rule 13d-1(b)(1)(ii)(G);

     (h)  [_]  A savings  association  as defined in Section 3(b) of the Federal
               Deposit Insurance Act;

     (i)  [_]  A  church  plan  that  is  excluded  from  the  definition  of an
               investment  company  under  Section  3(c)(14)  of the  Investment
               Company Act;

     (j)  [_]  Group, in accordance with Rule 13d-1(b)(1)(ii)(J).





CUSIP No. 082657107                   13G                      Page 4 of 5 Pages

Item 4.  Ownership.

     Provide  the  following  information  regarding  the  aggregate  number and
percentage of the class of securities of the issuer identified in Item 1.

     (a)  Amount beneficially owned:

          At  April  1,  2002,  Renaissance  US  Growth  and  Income  Trust  PLC
          ("Renaissance  US" or "Filer") owned 1,104,400 shares of the Company's
          common stock.  During April,  Renaissance US sold the Company's common
          stock as follows:  April 8, 2002,  52,800  shares at $10.07 per share;
          April 9, 2002,  97,200  shares at $10.15;  and April 10, 2002,  50,000
          shares at $10.11 per share.  Thus, at April 30, 2002,  the Filer owned
          904,400  shares of the  Company's  common  stock on a fully  converted
          basis.

          The  Investment  Adviser for  Renaissance  US is  Renaissance  Capital
          Group, Inc., which is also Investment Adviser for Renaissance  Capital
          Growth and Income Fund III,  Inc.  ("Renaissance  III") and for BFS US
          Special  Opportunities  Trust PLC ("BFS US"). Both  Renaissance US and
          BFS US also own shares of Bentley Pharmaceuticals, Inc.

          ______________________________________________________________________

     (b)  Percent of class:
          6.15%
          ______________________________________________________________________

     (c)  Number of shares as to which such person has:

          (i)   Sole power to vote or to direct the vote
                904,400

          (ii)  Shared power to vote or to direct the vote
                None

          (iii) Sole power to dispose or to direct the disposition of
                904,400

          (iv)  Shared power to dispose or to direct the disposition of
                None

Item 5.  Ownership of Five Percent or Less of a Class.

     If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities check the following [ ].
         _______________________________________________________________________

Item 6.  Ownership of More Than Five Percent on Behalf of Another Person.

         Not applicable
         _______________________________________________________________________

Item 7.  Identification and  Classification of the Subsidiary Which Acquired the
         Security  Being  Reported on by the Parent  Holding  Company or Control
         Person.

         Not applicable
         _______________________________________________________________________

Item 8.  Identification  and  Classification  of Members of the Group.

         Not applicable

CUSIP No. 082657107                   13G                      Page 5 of 5 Pages
         _______________________________________________________________________

Item 9.  Notice of Dissolution of Group.

         Not applicable
         _______________________________________________________________________

Item 10.  Certifications.

     (a)  The  following  certification  shall be included if the  statement  is
          filed pursuant to Rule 13d-1(b):

          "By signing  below I certify  that,  to the best of my  knowledge  and
          belief, the securities referred to above were acquired and are held in
          the ordinary course of business and were not acquired and not held for
          the  purpose  of or with the effect of  changing  or  influencing  the
          control of the issuer of the  securities and were not acquired and are
          not held in  connection  with or as a participant  in any  transaction
          having such purpose or effect."


     (b)  The  following  certification  shall be included if the  statement  is
          filed pursuant to Rule 13d-1(c):

          "By signing  below I certify  that,  to the best of my  knowledge  and
          belief, the securities referred to above were not acquired and are not
          held for the purpose of or with the effect of changing or  influencing
          the control of the issuer of the  securities and were not acquired and
          are not held in connection with or as a participant in any transaction
          having such purpose or effect."


                                    SIGNATURE

     After  reasonable  inquiry and to the best of my  knowledge  and belief,  I
certify that the information  set forth in this statement is true,  complete and
correct.


                                                     May 9, 2002
                                        ----------------------------------------
                                                        (Date)


                                          /S/  Russell Cleveland
                                        ----------------------------------------
                                                      (Signature)

                                        Russell Cleveland, President and CEO
                                        Renaissance Capital Growth & Income
                                             Fund III, Inc.
                                        ----------------------------------------
                                                      (Name/Title)